← Leaderboards
Andrew Lewis Feldman
Mayo Clinic Rochester
$5,717,562
Attributed
$5,717,562
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2013–22$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$11,861,403 · 4
By mechanism
P01$9,151,318 · 2
R01$1,639,727 · 1
P50$1,070,358 · 1
Top collaborators
- Lisa Rimsza3 shared
- David William Scott3 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Howard J Rosen$46,265,858
- Surendra Dasari$464,470
- Devin Oglesbee$1,434,107
- Ian R Lanza$12,553,585
- Shounak Majumder$1,478,216
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsLymphomaTumorDiagnosisBaseTranslational ResearchCellsTumor TissueResearch PersonnelClinicInnovationLeadBiometryGene ExpressionGeneticPathway InteractionsT-Cell LymphomaBioinformaticsProgramsPathologySamplingClassificationMolecular ProfilingHematology
Grant awards (17)
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma$1,913,660
P01 · FY2022 · CA
Molecular Classification of Anaplastic Large Cell Lymphoma$604,916
P01 · FY2022 · CA · contact PI
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma$2,117,897
P01 · FY2021 · CA
Molecular Classification of Anaplastic Large Cell Lymphoma$594,813
P01 · FY2021 · CA · contact PI
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma$2,112,284
P01 · FY2020 · CA
Molecular Classification of Anaplastic Large Cell Lymphoma$594,811
P01 · FY2020 · CA · contact PI
Core B: Biospecimens$265,057
P50 · FY2020 · CA · contact PI
Molecular Classification of Anaplastic Large Cell Lymphoma$601,626
P01 · FY2019 · CA · contact PI
Core B: Biospecimens$261,505
P50 · FY2019 · CA · contact PI
Molecular Classification of Anaplastic Large Cell Lymphoma$611,311
P01 · FY2018 · CA · contact PI
Core B: Biospecimens$279,352
P50 · FY2018 · CA · contact PI
Genetic Biomarkers for Risk Assessment of Peripheral T-Cell Lymphomas$329,925
R01 · FY2017 · CA · contact PI
Core B: Biospecimens$264,444
P50 · FY2017 · CA · contact PI
Genetic Biomarkers for Risk Assessment of Peripheral T-Cell Lymphomas$329,925
R01 · FY2016 · CA · contact PI
Genetic Biomarkers for Risk Assessment of Peripheral T-Cell Lymphomas$329,925
R01 · FY2015 · CA · contact PI
Genetic Biomarkers for Risk Assessment of Peripheral T-Cell Lymphomas$320,027
R01 · FY2014 · CA · contact PI
Genetic Biomarkers for Risk Assessment of Peripheral T-Cell Lymphomas$329,925
R01 · FY2013 · CA · contact PI